Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2023
Programm
Suche
DE
Alle Personen
Uwe Reuter
Sortiert nach Typ
Datum
Vorsitz
06.12.2023
14:40
–
15:55
Plenary session
PS 3 & Opening | Role of the calvarium, brain immune barriers and fluid transport
Plenary hall
07.12.2023
09:45
–
11:15
Scientific session
ScS 4 | Biomarkers and pathophysiology in migraine
Breakout room 1
07.12.2023
14:00
–
15:15
Debate session
DS 1 | The EHF debate on acute migraine medication
Plenary hall
Invited speaker
Other
Welcome by the congress chairs
Vortrag
ePoster
P019
Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2–4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
Weitere Beteiligungen
ePoster
P019
Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2–4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
ePoster
P022
Atogepant demonstrates early functional and quality of life improvements for the preventive treatment of episodic migraine after prior inadequate response to treatment: results from the ELEVATE trial
ePoster
P179
Visual snow syndrome in patients with migraine from a tertiary headache center: prevalence, phenomenology and impact on quality of life
ePoster
P180
Alice in Wonderland Syndrome (AIWS) and migraine: prevalence and characteristics of AIWS in adults with migraine
ePoster
P096
Atogepant provides early improvements in daily functioning and quality of life: results from the PROGRESS chronic migraine trial
ePoster
LP051
Reimbursement rules for CGRP mAbs throughout europe: an overview of the various constraints used
ePoster
P260
Predictors of response to anti-CGRP monoclonal antibodies: a scoping review and meta-analysis of real-world experience
v1.21.0
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz